Navigation Links
Recurrent Gliomas: Vorinostat Shows Anti-cancer Activity

CHICAGO Findings presented today at the American Society of Clinical Oncology Annual Meeting by Eva Galanis, M.D., a Mayo Clinic oncologist, reveals that a novel application of the drug vorinostat shows activity in patients with recurrent glioblastoma multiforme. The study was conducted by North Central Cancer Treatment Group (NCCTG) researchers, based at Mayo Clinic in Rochester, Minn. Eva is the lead investigator of the study.

Glioblastoma multiforme is a lethal primary brain tumor. The average survival of glioblastoma patients is 12-16 months. These tumors spread quickly to other parts of the brain, and because of this are difficult to treat and often recur. When the tumor recurs, treatment options are limited, and patients survive for an average of three to four months.

"Existing treatment interventions have minimal impact on the outcome of recurrent glioblastoma multiforme patients," Dr. Galanis says. "Using vorinostat to treat glioblastoma multiforme patients who have relapsed following surgery, radiation and chemotherapy, we found that 15 percent of the patients had no tumor recurrence for six months or longer following treatment initiation. The median overall survival of the patients enrolled on the trial was 5.7 months -- similar patient populations enrolled in prior NCCTG trials had a median overall survival of between 4 and 4.4 months."

This study was the first application of vorinostat in targeting brain cancer. Vorinostat is approved by the U.S. Food and Drug Administration (FDA) for the treatment of cutaneous T cell lymphoma in patients who have failed two or more systemic therapies.

An additional group of patients in this study was treated with vorinostat prior to surgery, and a gene and protein analysis of their resected tumors was performed. This analysis confirmed increase in histone acetylation and showed gene changes indicating that vorinostat reaches the glioblastoma tumors and interferes with the target pathways. Dr. Galanis says the researchers plan to expand this analysis to all study patients. This will help define a patient population that has a higher likelihood of benefiting from treatment -- allowing treatment individualization in the future.

Vorinostat is the first FDA approved oral anti-cancer agent that inhibits an enzyme, histone deacetylase, that is closely associated with DNA in cells. By inhibiting the deacetylation of histones -- proteins that help organize the structure of DNA -- vorinostat alters the expression of several important genes and proteins resulting in tumor cell death and stopping tumor growth.

Dr. Galanis says that study findings indicate that vorinostat by itself shows anti-cancer activity in glioblastoma multiforme. Plans are ongoing to combine vorinostat with other drugs in future clinical trials for brain tumor patients.


'"/>




Related medicine news :

1. Estrogen Does Not Prevent Recurrent Strokes
2. Radiation Therapy An Effective Solution For Recurrent Prostate Cancer
3. Prevention Of Recurrent Leg Ulcers
4. Measuring Urinary Protein Helps In Detecting Recurrent Bladder Cancer
5. Sertraline Can Prevent Recurrent Depressive Episodes In Diabetics
6. Angola Warned of Recurrent Cholera Outbreaks
7. Gemzar the New Drug for Recurrent Ovarian Cancer
8. Recurrent Stroke Risk is Minimized by Statin
9. Blood Markers Predict Risk for Recurrent Stroke and Mortality
10. Targeted Compound Helps Recurrent Prostate Cancer Patients
11. Ancient Indian Herb May Prove Cure For Recurrent UTI
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their ... Eyeglasses . , Millions of individuals in the United States and Canada wear eyeglasses. ... way to both correct vision and make a fashion statement. Even celebrities use glasses ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: